Genmab Feed

2024-10-15 12:25:43 Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2024 -0,28% | 580 MDKK

2024-10-04 19:55:34 Major Shareholder Announcement

2024-09-26 21:17:37 Grant of Restricted Stock Units and Warrants to Employees in Genmab +1,53% | 748 MDKK

2024-09-15 14:45:00 Investigational Rinatabart Sesutecan (Rina-S) Shows Promising Anti-Tumor Activity as Single Agent in Heavily Pretreated Patients with Ovarian and Endometrial Cancers in Phase 1/2 Clinical Trial

2024-09-10 22:06:46 Capital Increase in Genmab as a Result of Employee Warrant Exercise -2,37% | 416 MDKK

2024-08-26 18:26:06 Genmab to Present at Morgan Stanley 22nd Annual Global Healthcare Conference +1,55% | 903 MDKK

2024-08-19 20:00:00 TEPKINLY® (epcoritamab) Receives Second European Commission Approval for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma -2,23% | 849 MDKK

2024-08-16 15:00:00 Genmab Announces Changes to its Executive Committee -0,73% | 434 MDKK

2024-08-13 20:53:20 Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons +0,69% | 612 MDKK

2024-08-13 20:51:01 Capital Increase in Genmab as a Result of Employee Warrant Exercise +0,69% | 612 MDKK

2024-08-08 17:03:14 Genmab Announces Financial Results for the First Half of 2024 -1,18% | 695 MDKK

2024-08-08 17:00:38 Genmab Updates 2024 Financial Guidance -1,18% | 695 MDKK

2024-08-05 11:50:00 Genmab Takes Full Control of Acasunlimab Development Program -7,36% | 913 MDKK

2024-07-17 12:25:09 Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2024 +0,05% | 630 MDKK

2024-06-28 08:00:00 Epcoritamab (TEPKINLY®) Receives Positive CHMP Opinion for the Treatment of Adults with Relapsed/ Refractory Follicular Lymphoma -1,88% | 748 MDKK

2024-06-27 23:00:10 Completion of Share Buy-back Program -1,88% | 748 MDKK

2024-06-27 01:03:00 EPKINLY® (epcoritamab-bysp) Approved by U.S. FDA for Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL) -0,44% | 720 MDKK

2024-06-24 15:55:32 Transactions in Connection with Share Buy-back Program -0,06% | 688 MDKK

2024-06-18 20:45:17 Capital Increase in Genmab as a Result of Employee Warrant Exercise -2,90% | 668 MDKK

2024-06-17 15:33:09 Transactions in Connection with Share Buy-back Program -1,80% | 984 MDKK

2024-06-12 21:45:09 Grant of Restricted Stock Units and Warrants to Employees in Genmab -1,25% | 690 MDKK

2024-06-11 20:50:48 Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons -2,48% | 1371 MDKK

2024-06-10 16:18:41 Transactions in Connection with Share Buy-back Program -0,39% | 554 MDKK

2024-06-05 18:51:07 Genmab to Participate in a Fireside Chat at the Goldman Sachs 45th Annual Global Healthcare Conference +0,15% | 836 MDKK

2024-06-03 15:09:23 Transactions in Connection with Share Buy-back Program +0,85% | 1355 MDKK

2024-06-03 15:00:00 Investigational Tisotumab Vedotin Phase 2 Data Demonstrates Encouraging Antitumor Activity in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) +0,85% | 1355 MDKK

2024-06-02 23:30:00 Preliminary Analysis of Data Evaluating Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Demonstrates 95% Overall Response Rate in Patients with Previously Untreated Follicular Lymphoma +0,85% | 1355 MDKK

2024-06-01 16:00:00 Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)

2024-05-27 16:16:29 Transactions in Connection with Share Buy-back Program +1,48% | 746 MDKK

2024-05-23 23:00:00 Genmab to Showcase Data in Various Patient Populations to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting -4,86% | 1624 MDKK

2024-05-21 17:06:00 Genmab Completes Acquisition of ProfoundBio +2,65% | 759 MDKK

2024-05-21 13:19:26 Transactions in Connection with Share Buy-back Program -1,91% | 588 MDKK

2024-05-14 16:02:00 Genmab to Present New and Updated Results From Multiple Clinical Trials Evaluating Epcoritamab Across Various B-Cell Malignancies at the 2024 European Hematology Association (EHA) Congress +1,76% | 905 MDKK

2024-05-13 16:09:25 Transactions in Connection with Share Buy-back Program -0,65% | 563 MDKK

2024-05-07 20:27:18 Capital Increase in Genmab as a Result of Employee Warrant Exercise -0,45% | 488 MDKK

2024-05-06 16:01:54 Transactions in Connection with Share Buy-back Program -2,77% | 920 MDKK

2024-05-02 17:01:39 Genmab Announces Financial Results for the First Quarter of 2024 +5,91% | 913 MDKK

2024-04-30 00:40:00 TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer +0,79% | 690 MDKK

2024-04-29 10:24:29 Transactions in Connection with Share Buy-back Program Genmab +0,79% | 690 MDKK

2024-04-22 09:30:08 Transactions in Connection with Share Buy-back Program Genmab +1,20% | 1300 MDKK

2024-04-16 12:24:22 Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2024 0,00% | 1069 MDKK

2024-04-15 10:07:30 Transactions in Connection with Share Buy-back Program Genmab -0,44% | 757 MDKK

2024-04-08 11:44:15 Transactions in Connection with Share Buy-back Program -0,29% | 401 MDKK

2024-04-03 07:34:00 Genmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio -2,11% | 952 MDKK

2024-04-02 09:24:28 Transactions in Connection with Share Buy-back Program +0,10% | 1500 MDKK

2024-03-25 14:31:03 Transactions in Connection with Share Buy-back Program -0,82% | 826 MDKK

2024-03-18 10:49:07 Completion of share buy-back program -0,10% | 671 MDKK

2024-03-15 13:16:44 Genmab Announces Initiation of Share Buy-Back Program -2,15% | 773 MDKK

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Genmab

Språk

Typ

År

Språk

Typ

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden